[Form 4] NATIONAL HEALTHCARE CORP Insider Trading Activity
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
National Healthcare Corp. director Emil E. Hassan reported an option exercise that increased his direct common stock holdings. On April 30, 2026, he exercised an option for 7,500 shares of common stock at an exercise price of $71.64 per share, moving those shares into direct ownership so that he now holds 73,095 shares of common stock directly.
The exercised option was the 2021 grant, which covered 7,500 underlying shares at $71.64; that option position is now fully used with zero options remaining from that grant. He also continues to hold four other option grants under the company’s equity plans, each covering 7,500 underlying shares with exercise prices of $94.66, $96.03, $55.75, and $69.19, expiring between 2027 and 2030. A footnote states these stock options were granted under the 2020 Omnibus Equity Incentive Plan and that the grant and exercise are exempt from Section 16(b) under Rule 16b-3(d).
Positive
- None.
Negative
- None.
Insider Trade Summary
7,500 shares exercised/converted
Mixed
6 txns
Insider
HASSAN EMIL E
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Option to Purchase Common Stock [2021 Grant] | 7,500 | $0.00 | -- |
| Exercise | Shares of Common Stock | 7,500 | $71.64 | $537K |
| holding | Option to Purchase Common Stock [2022 Grant] | -- | -- | -- |
| holding | Option to Purchase Common Stock [2023 Grant] | -- | -- | -- |
| holding | Option to Purchase Common Stock [2024 Grant] | -- | -- | -- |
| holding | Option to Purchase Common Stock [2025 Grant] | -- | -- | -- |
Holdings After Transaction:
Option to Purchase Common Stock [2021 Grant] — 0 shares (Direct, null);
Shares of Common Stock — 73,095 shares (Direct, null);
Option to Purchase Common Stock [2022 Grant] — 7,500 shares (Direct, null);
Option to Purchase Common Stock [2023 Grant] — 7,500 shares (Direct, null);
Option to Purchase Common Stock [2024 Grant] — 7,500 shares (Direct, null);
Option to Purchase Common Stock [2025 Grant] — 7,500 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Options exercised: 7,500 shares
Exercise price (2021 grant): $71.64/share
Shares held after exercise: 73,095 shares
+4 more
7 metrics
Options exercised
7,500 shares
Common stock acquired via 2021 option grant exercise
Exercise price (2021 grant)
$71.64/share
Option to Purchase Common Stock [2021 Grant]
Shares held after exercise
73,095 shares
Total direct common stock ownership following transactions
2025 grant exercise price
$94.66/share
Remaining option grant, expires 2030-05-07
2024 grant exercise price
$96.03/share
Remaining option grant, expires 2029-05-08
2023 grant exercise price
$55.75/share
Remaining option grant, expires 2028-05-03
2022 grant exercise price
$69.19/share
Remaining option grant, expires 2027-05-04
Key Terms
Option to Purchase Common Stock, derivative exercise/conversion, 2020 Omnibus Equity Incentive Plan, Section 16(b), +1 more
5 terms
Option to Purchase Common Stock financial
"security_title: "Option to Purchase Common Stock [2025 Grant]""
derivative exercise/conversion financial
"transaction_action: "derivative exercise/conversion" for code M"
2020 Omnibus Equity Incentive Plan financial
"These stock options were granted pursuant to the 2020 Omnibus Equity Incentive Plan"
Section 16(b) regulatory
"The grant and exercise of these stock options are exempt from Section 16(b)"
A federal rule that requires company insiders—like officers, directors and large shareholders—to return any profits made from buying and selling the company’s stock within a six-month window. It matters to investors because it discourages short-term trades that could exploit non-public information and helps protect outside shareholders by creating a simple, enforceable way to recover unfair gains, much like a rule stopping someone from flipping a limited-edition item for quick profit after getting early access.
Rule 16b-3(d) regulatory
"exempt from Section 16(b) pursuant to Rule 16b-3(d)"
Rule 16b-3(d) is a narrow SEC safe-harbor that shields company insiders (officers, directors and large shareholders) from liability for short‑swing profits when their buys or sells of company stock are made under a pre-established, written plan or contract that removes the insider’s ability to time trades. For investors, this matters because it permits predictable, automated insider transactions — like scheduled sales for diversification or payroll withholding — without triggering forced disgorgement, so such planned trades are treated differently from opportunistic insider trading.
